Prelude Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage precision oncology company focused on discovering and developing highly selective, small-molecule cancer therapies. The company leverages its expertise in cancer biology and medicinal chemistry to target clinically validated pathways. Its primary pipeline focus centers on its mutant-selective JAK2V617F inhibitor program (PRT12396) and its highly selective oral KAT6A degrader program (PRT13722). Additionally, Prelude is utilizing its targeted protein degradation platform to develop next-generation degrader antibody conjugates (DACs) with novel payloads, including SMARCA2/4 and CDK9 degraders, in collaboration with partners like AbCellera Biologics.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In late 2025, Prelude executed a strategic shift to focus resources on its high-potential mutant-selective JAK2V617F inhibitor (PRT12396) and KAT6A degrader (PRT13722) programs. As part of this transition, clinical development of its SMARCA2 degrader program was paused, and workforce reductions were implemented to optimize capital efficiency.
Expected impact: Extends cash runway, reduces operating expenses (R&D expenses decreased to $94.3 million in 2025 from $118.0 million in 2024), and concentrates clinical focus on highly differentiated assets.
Leveraging its proprietary protein degradation expertise to discover and develop next-generation DACs using novel payloads (such as SMARCA2/4 and CDK9 degraders) and targeting neoantigens like mutated calreticulin (mCALR).
Expected impact: Expands the therapeutic utility of protein degraders into precision antibody-drug conjugates, creating opportunities for proprietary pipeline growth and out-licensing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides non-dilutive funding and a strong global development partner for the mutant-selective JAK2V617F JH2 inhibitor program.
Terms: Prelude received $60 million in near-term capital, consisting of a $35 million upfront cash payment and a $25 million equity investment from Incyte. Incyte holds an exclusive option to acquire the program.
Combines AbCellera's antibody discovery engine with Prelude's expertise in small molecule and degrader payloads to jointly discover, develop, and commercialize novel degrader antibody conjugates (DACs) for up to five programs.
Terms: Amended and expanded in 2H 2025 to grant AbCellera non-exclusive licenses to certain Prelude degrader payloads for independent development, providing upfront license payments and shifting development costs for those licensed programs entirely to AbCellera.
Evaluates PRT3789, Prelude's investigational SMARCA2 degrader, in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with SMARCA4-mutated cancers.
Terms: Prelude sponsors the clinical trial, and Merck provides KEYTRUDA.